-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TMwfLdWnJTX8mCmZBr+LKhMEjYhAIIfpP/uFmqp4Jxi6/vE0pdNXKNlhxOtdlBh7 4TMShnOb4N8IDwprTkTxww== 0001341004-08-000166.txt : 20080131 0001341004-08-000166.hdr.sgml : 20080131 20080131070910 ACCESSION NUMBER: 0001341004-08-000166 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080130 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080131 DATE AS OF CHANGE: 20080131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENELABS TECHNOLOGIES INC /CA CENTRAL INDEX KEY: 0000874443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943010150 STATE OF INCORPORATION: CA FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19222 FILM NUMBER: 08562681 BUSINESS ADDRESS: STREET 1: 505 PENOBSCOT DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 6503969500 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 8-K 1 genelabs8k1-29.htm FORM 8-K genelabs8k1-29.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


    Date of Report (Date of earliest event reported)
January 29, 2008
   
   
 
Genelabs Technologies, Inc.
 
(Exact name of registrant as specified in its charter)
  
     
     
     
 
California
0-19222
94-3010150
 
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
  
     
     
 
505 Penobscot Drive, Redwood City, California
94063
 
(Address of principal executive offices)
(Zip Code)
  
     
     
 
Registrant’s telephone number, including area code
(650) 369-9500
     
     
   
 
(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 5.02         Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
 
On January 29, 2008, James A.D. Smith announced his resignation as President and Chief Executive Officer and as a member of the Board of Directors of Genelabs Technologies, Inc. (the “Registrant”), effective immediately.
 
During the search for a new President and Chief Executive Officer, Irene A. Chow, Ph.D., age 68, Executive Chairman of the Registrant's Board of Directors, and Frederick W. Driscoll, age 57, Chief Financial Officer, will assume leadership responsibilities of the Registrant until a successor is appointed. 
 
         Dr. Chow has been Chairman of the Board since April 1999 and was Chief Executive Officer from January 2001 to March 2004. From 1995 through March 1999 she was President and Chief Executive Officer.  Dr. Chow served as a director of the board of Genovate Biotechnology Co., Ltd. (formerly Genelabs Biotechnology Co., Ltd.) throughout 2006, resigning in January 2007.  Until June 2005, Dr. Chow served as chairman of the Genovate board.  Before joining the Registrant, Dr. Chow held several positions at Ciba-Geigy Corporation, most recently as Senior Vice President of Drug Development for the pharmaceuticals division.  Prior to joining Ciba-Geigy, Dr. Chow served as an associate professor and assistant dean of Health Related Professions at Downstate Medical School, State University of New York.  Dr. Chow received her B.A. degree in Literature from National Taiwan University, and both an M.A. and a Ph.D. in Biostatistics from the University of California, Berkeley.

         Mr. Driscoll has been Chief Financial Officer of the Registrant since November 1, 2007.  He joined the Registrant from Astraris, Inc., a start-up biotechnology company developing vascular-disrupting technology to treat solid tumors, where he served as Chief Financial Officer.  From 2000 to 2006, he was employed by OXiGENE, Inc., initially as Vice President of Finance and Operations and subsequently as President and Chief Executive Officer.  Previously Mr. Driscoll served as Senior Vice President of Finance and Operations for Collagenesis Corporation and Vice President of Finance over the Americas for Instrumentation Laboratory.
 
A copy of the press release issued by the Registrant announcing the resignation of Mr. Smith is filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01.      Financial Statements and Exhibits
 
(d) Exhibits
 
Exhibit
Number
Description
99.01
Press Release of Genelabs Technologies, Inc., dated January 30, 2008

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


   
Genelabs Technologies, Inc.
         
         
Date: January 30, 2008
By:
/s/ Frederick W. Driscoll
     
Name:
Frederick W. Driscoll
     
Title:
Chief Financial Officer



EXHIBIT INDEX

Exhibit
Number
Description
99.01
Press Release of Genelabs Technologies, Inc., dated January 30, 2008

EX-99.01 2 ex99-01.htm EXHIBIT 99.01 - PRESS RELEASE ex99-01.htm
 
 
EXHIBIT 99.01

Genelabs Technologies, Inc. Announces Resignation of President and CEO

Executive Chairman and CFO Assume Leadership Responsibilities; CEO Search Underway

REDWOOD CITY, Calif. - January 30, 2008 - Genelabs Technologies, Inc. (NASDAQ: GNLB) announced today that James A. D. Smith has resigned as President, Chief Executive Officer and Director of the company, effective January 29, 2008. Irene A. Chow, Ph.D., Executive Chairman of Genelabs’ Board of Directors, and Frederick W. Driscoll, Genelabs’ Chief Financial Officer, will assume leadership responsibilities until a successor is appointed.

Dr. Chow stated, “I want to thank Jim for his dedication and many years of service to the company.  We wish him well in his future endeavors. The company has initiated an executive search for a CEO to lead it into the next phase of its development.”

“Genelabs is well-positioned to execute on its internal development strategies and to support its collaboration partners – Gilead, GlaxoSmithKline and Novartis. We are fully committed and confident about our ability to deliver on our business goal of translating research into novel antiviral therapeutics,” stated Mr. Driscoll.

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program.  We also have late-stage products for hepatitis E virus and lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit www.genelabs.com.

Note: Genelabs® and the Genelabs logo are registered trademarks of Genelabs Technologies, Inc.
 
NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements regarding the Company’s business strategy. These forward-looking statements are based on Genelabs’ current expectations and are subject to uncertainties and risks, including failures or setbacks in our hepatitis C virus research and development programs or in our collaborations with Gilead, GlaxoSmithKline and Novartis. Please see the information appearing in Genelabs’ filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, under the captions “Risk Factors” and “Forward-Looking Statements” for more discussion regarding these uncertainties and risks and others associated with the company's research programs, early stage of development and other risks which may affect the company or cause actual results to differ from those included in the forward-looking statements. Genelabs does not undertake any obligation to update these forward-looking statements or risks to reflect events or circumstances after the date of this release.

SOURCE: Genelabs Technologies, Inc.
 -----END PRIVACY-ENHANCED MESSAGE-----